Comparative Pharmacology
Head-to-head clinical analysis: TOFACITINIB CITRATE versus VIVJOA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOFACITINIB CITRATE versus VIVJOA.
TOFACITINIB CITRATE vs VIVJOA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Janus kinase (JAK) inhibitor; inhibits JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), thereby modulating cytokine signaling and downregulating immune and inflammatory responses.
VIVJOA (fosmanogepix) is a first-in-class antifungal agent that inhibits the fungal enzyme Gwt1, which is involved in glycosylphosphatidylinositol (GPI) anchor biosynthesis. This disrupts cell wall integrity and fungal growth.
5 mg orally twice daily for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis; 10 mg orally twice daily for ulcerative colitis induction (8 weeks maximum).
VIVJOA (750 mg tablet) is administered as a single oral dose of 750 mg, taken once daily for 6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours (range 2–4 hours) in patients with normal renal function, allowing twice-daily dosing. Half-life is prolonged in moderate to severe renal impairment (up to 5–8 hours) and in hepatic impairment.
Terminal elimination half-life is approximately 20–26 hours, supporting once-daily dosing for sustained therapeutic levels.
Approximately 70% of the dose is eliminated by hepatic metabolism, with about 30% excreted unchanged in urine and <10% in feces. Renal excretion accounts for ~30% of total clearance.
Primarily hepatic metabolism via CYP3A4, with <1% excreted unchanged in urine; fecal elimination accounts for approximately 88% of the administered dose as metabolites.
Category D/X
Category C
JAK Inhibitor
JAK Inhibitor